TY - JOUR
T1 - Non-criteria antiphospholipid antibodies and calprotectin as potential biomarkers in pediatric antiphospholipid syndrome
AU - Sloan, Elizabeth E.
AU - Kmetova, Katarina
AU - NaveenKumar, Somanathapura K.
AU - Kluge, Lyndsay
AU - Chong, Emily
AU - Hoy, Claire K.
AU - Yalavarthi, Srilakshmi
AU - Sarosh, Cyrus
AU - Baisch, Jeanine
AU - Walters, Lynnette
AU - Nassi, Lorien
AU - Fuller, Julie
AU - Turnier, Jessica L.
AU - Pascual, Virginia
AU - Wright, Tracey B.
AU - Madison, Jacqueline A.
AU - Knight, Jason S.
AU - Zia, Ayesha
AU - Zuo, Yu
N1 - Publisher Copyright:
© 2023
PY - 2024/4
Y1 - 2024/4
N2 - Our study aimed to evaluate the presence, clinical associations, and potential mechanistic roles of non-criteria antiphospholipid antibodies (aPL) and circulating calprotectin, a highly stable marker of neutrophil extracellular trap release (NETosis), in pediatric APS patients. We found that 79% of pediatric APS patients had at least one non-criteria aPL at moderate-to-high titer. Univariate logistic regression demonstrated that positive anti-beta-2 glycoprotein I domain 1 (anti-D1) IgG (p = 0.008), anti-phosphatidylserine/prothrombin (aPS/PT) IgG (p < 0.001), and aPS/PT IgM (p < 0.001) were significantly associated with venous thrombosis. Positive anti-D1 IgG (p < 0.001), aPS/PT IgG (p < 0.001), and aPS/PT IgM (p = 0.001) were also associated with non-thrombotic manifestations of APS, such as thrombocytopenia. Increased levels of calprotectin were detected in children with APS. Calprotectin correlated positively with absolute neutrophil count (r = 0.63, p = 0.008) and negatively with platelet count (r = −0.59, p = 0.015). Mechanistically, plasma from pediatric APS patients with high calprotectin levels impaired platelet viability in a dose-dependent manner.
AB - Our study aimed to evaluate the presence, clinical associations, and potential mechanistic roles of non-criteria antiphospholipid antibodies (aPL) and circulating calprotectin, a highly stable marker of neutrophil extracellular trap release (NETosis), in pediatric APS patients. We found that 79% of pediatric APS patients had at least one non-criteria aPL at moderate-to-high titer. Univariate logistic regression demonstrated that positive anti-beta-2 glycoprotein I domain 1 (anti-D1) IgG (p = 0.008), anti-phosphatidylserine/prothrombin (aPS/PT) IgG (p < 0.001), and aPS/PT IgM (p < 0.001) were significantly associated with venous thrombosis. Positive anti-D1 IgG (p < 0.001), aPS/PT IgG (p < 0.001), and aPS/PT IgM (p = 0.001) were also associated with non-thrombotic manifestations of APS, such as thrombocytopenia. Increased levels of calprotectin were detected in children with APS. Calprotectin correlated positively with absolute neutrophil count (r = 0.63, p = 0.008) and negatively with platelet count (r = −0.59, p = 0.015). Mechanistically, plasma from pediatric APS patients with high calprotectin levels impaired platelet viability in a dose-dependent manner.
KW - Antiphospholipid syndrome
KW - Calprotectin
KW - Non-criteria antiphospholipid antibodies
KW - Pediatric
KW - Thrombocytopenia
UR - http://www.scopus.com/inward/record.url?scp=85185588890&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85185588890&partnerID=8YFLogxK
U2 - 10.1016/j.clim.2024.109926
DO - 10.1016/j.clim.2024.109926
M3 - Article
C2 - 38355030
AN - SCOPUS:85185588890
SN - 1521-6616
VL - 261
JO - Clinical Immunology
JF - Clinical Immunology
M1 - 109926
ER -